Drug Research
Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo
Duality Biologics, a clinical-stage biotech company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers and autoimmune diseases, announced a license agreement with Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough...
Drug Research
WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
WuXi Biologics , a leading global Contract Research, Development, and Manufacturing Organization announced a license agreement with GSK plc under which GSK will have exclusive licenses for up to four bi- & multi-specific TCE antibodies developed using WuXi Biologics' proprietary...
Drug Research
Moderna to Acquire OriCiro Genomics for $85M
Moderna has announced it will acquire Japan-based DNA supplier OriCiro Genomics K.K (OriCiro) for $85m, marking the US company’s first acquisition since its 2010 launch.
Through the acquisition, Moderna will obtain OriCiro’s tools for cell-free synthesis and amplification of plasmid...
Drug Research
Capsida Biotherapeutics, Prevail Therapeutics Enter Strategic R&D Alliance
Capsida Biotherapeutics Inc. has entered a multi-year strategic collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Co., to develop genetic medicines for serious diseases. Prevail will leverage Capsida's novel adeno-associated virus (AAV) engineering platform to...
Drug Research
Australia Implements New Measure To Lower Cost of Medicines
Millions of Australians will pay up to 29% less for their Pharmaceutical Benefits Scheme (PBS) prescriptions because the maximum PBS co-payment is going down from $42.50 to $30. The co-payment for general scripts has decreased for the first time...
Drug Research
Biognosys and Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma and Biomarker Customers
Bruker Corporation and Switzerland-based Biognosys AG announced a strategic partnership, in which Bruker has made a majority-ownership investment in Biognosys. Financial details were not disclosed. J.P.Morgan acted as exclusive financial advisor to Biognosys. Several of Biognosys’ earlier investors have sold...
Drug Research
ASLAN, Thermo Fisher Join To Manufacture High Concentration Formulation Of Eblasakimab
ASLAN Pharmaceuticals , a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, and Thermo Fisher Scientific Inc, the world leader in serving science, today announced a partnership to manufacture a high concentration formulation of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read